Meeting
2015 Gastrointestinal Cancers Symposium
EGFR ligands and ERCC1 mRNA expression to predict clinical outcome in Japanese (JPN) patients (pts) with metastatic colorectal cancer (mCRC) harboring overexpressed EGFR and KRAS exon 2 wild-type (KRAS wt) treated with cetuximab (cet) plus oxaliplatin-based chemotherapy (JACCRO CC-05/06 AR).
Authors
Yu Sunakawa
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA
Yu Sunakawa , Wataru Ichikawa , Akihito Tsuji , Miriana Moran , Stephanie H. Astrow , Dongyun Yang , Wu Zhang , Takehiro Takahashi , Tadamichi Denda , Ken Shimada , Mitsugu Kochi , Masato Nakamura , Masahito Kotaka , Yoshihiko Segawa , Masahiro Takeuchi , Heinz-Josef Lenz , Masashi Fujii , Toshifusa Nakajima
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 618)
DOI
10.1200/jco.2015.33.3_suppl.618
Abstract #
618
Poster Bd #
C10
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
Association of EGFR CA simple sequence repeat 1 (CA-SSR1) variant with cetuximab (cet)-induced skin toxicity (ST) in Japanese metastatic colorectal cancer (mCRC) patients (pts) with overexpressed EGFR and KRAS exon 2 wild-type (KRAS wt) (JACCRO CC-05/06 AR).
First Author: Wataru Ichikawa
Poster
2012 ASCO Annual Meeting
Ligand expression of the EGFR ligands amphiregulin, epiregulin, and amplification of the EGFR gene to predict for treatment efficacy in KRAS wild-type mCRC patients treated with cetuximab plus CAPIRI and CAPOX: Analysis of the randomized AIO CRC-0104 trial.
First Author: Sebastian Stintzing
Poster
2014 ASCO Annual Meeting
Analysis of progression-free survival in the new EPOC study in an “all wild-type” population.
First Author: John A. Bridgewater
Poster
2012 Markers in Cancer
Use of epiregulin (EREG) and amphiregulin (AREG) gene expression to predict response to cetuximab (cet) in combination with oxaliplatin (Ox) and 5FU in the first-line treatment of advanced colorectal cancer (aCRC).
First Author: Richard Adams